Cryoport Inc
NASDAQ:CYRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cryoport Inc
NASDAQ:CYRX
|
US |
|
Glory Mark Hi-Tech (Holdings) Ltd
HKEX:8159
|
HK |
|
C
|
Chalice Brands Ltd.
CNSX:CHAL
|
CA |
|
Access Intelligence PLC
LSE:ACC
|
UK |
|
S
|
SemCNS Co Ltd
KOSDAQ:252990
|
KR |
|
Television Francaise 1 SA
PAR:TFI
|
FR |
|
Future Data Group Ltd
HKEX:8229
|
KR |
|
Medexus Pharmaceuticals Inc
TSX:MDP
|
CA |
|
M
|
Mycron Steel Bhd
KLSE:MYCRON
|
MY |
|
T
|
Tempo Scan Pacific Tbk PT
IDX:TSPC
|
ID |
|
A
|
Aritzia Inc
OTC:ATZAF
|
CA |
|
S
|
Shanghai Fudan Forward S&T Co Ltd
SSE:600624
|
CN |
Cryoport Inc
CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. The company is headquartered in Brentwood, Tennessee and currently employs 791 full-time employees. The company went IPO on 2015-07-24. The firm provides supply chain technologies and services through its brands, such as Cryoport Systems, CryoStork, MVE Biological Solutions, CRYOPDP, and CRYOGENE. The firm's products include Cryoport Express Shippers, Cryoport ELITE Shippers, Cryoport Cryosphere, Cryoport Consulting Services, Cryoport Bioservices, CRYOGENE, CRYOPDP Temperature Controlled Logistics, CRYOPDP Direct to Patient Solutions, CRYOPDP Control Tower Solution, MVE Biological Solutions Fusion Cryogenic Freezers and MVE Biological Solutions Vario Cryogenic Freezer. The company operates primarily in Americas; Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC). Its subsidiaries include Cryoport Systems, LLC, Cryogene, Inc., MVE Biological Solutions, US LLC, Cryoport Netherlands B.V., and Cell&Co BioServices.
CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. The company is headquartered in Brentwood, Tennessee and currently employs 791 full-time employees. The company went IPO on 2015-07-24. The firm provides supply chain technologies and services through its brands, such as Cryoport Systems, CryoStork, MVE Biological Solutions, CRYOPDP, and CRYOGENE. The firm's products include Cryoport Express Shippers, Cryoport ELITE Shippers, Cryoport Cryosphere, Cryoport Consulting Services, Cryoport Bioservices, CRYOGENE, CRYOPDP Temperature Controlled Logistics, CRYOPDP Direct to Patient Solutions, CRYOPDP Control Tower Solution, MVE Biological Solutions Fusion Cryogenic Freezers and MVE Biological Solutions Vario Cryogenic Freezer. The company operates primarily in Americas; Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC). Its subsidiaries include Cryoport Systems, LLC, Cryogene, Inc., MVE Biological Solutions, US LLC, Cryoport Netherlands B.V., and Cell&Co BioServices.
Revenue: Cryoport reported full year 2025 revenue from continuing operations of $176.2 million, exceeding the high end of prior guidance.
Commercial Momentum: Commercial cell & gene therapy revenue grew 29% YoY to $33.4 million for 2025 and represented ~20% of revenue in Q4; management expects commercial approvals to drive future growth.
Pipeline: Company supports a record 760 clinical trials (net +59 YoY) including 86 Phase III and 361 Phase II, and expects 13 BLA/MAA filings and 9 new therapy approvals in 2026.
Profitability Path: Gross margin was 47% in 2025; adjusted EBITDA improved by $12 million YoY and the company expects to be adjusted EBITDA positive in the second half of 2026.
2026 Outlook: Management guided full year 2026 revenue to $190.0 million–$194.0 million and described the midpoint as a conservative starting point given macro uncertainty.
Strategic Partnerships: Completed sale of CRYOPDP to DHL (completed in Q2 2025) and signaled partnerships with Cardinal Health and Parexel to broaden ecosystem and standardize offerings.
Product & Innovation: MVE revenue grew 7% for 2025; new product launches include Fusion 800 Series freezers and integrated condition monitoring tied to a new Cryoverse cloud platform.
Operational Notes: Investing in Global Supply Chain Centers (Paris, Santa Ana) and rapid build-out (Belgium) to support large commercial customers; no material flight disruption expected for Q1.
